Autologous mDA Progenitor Cell Therapy for Parkinson's Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological treatments for Parkinson's disease, such as dopamine replacement therapies, lead to undesirable side effects like dyskinesias and motor fluctuations, and there is a need for a more effective and safe therapeutic strategy to address the loss of midbrain dopamine neurons.
Innovation Solution
A method is developed to generate clinical-grade midbrain dopamine neuronal progenitor cells using induced pluripotent stem cells, combining metabolism-regulating microRNAs with reprogramming factors, and a 'spotting'-based differentiation process to produce functional and healthy dopaminergic cells, with a chemical method to eliminate undifferentiated cells, suitable for autologous cell therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dopamine replacement therapy is used to treat Parkinson's disease, then motor function is improved, but side effects such as dyskinesias and motor fluctuations occur
Solution Approach 1:
The patent extracts the therapeutic benefit of dopamine replacement while eliminating the harmful side effects by transplanting functional dopamine neurons directly into the patient's brain. This replaces the pharmacological approach with a cellular therapy that restores endogenous dopamine production without the adverse effects of exogenous dopamine or L-DOPA administration.
Solution Approach 2:
The patent uses induced pluripotent stem cells (iPSCs) as an intermediary to generate patient-specific midbrain dopamine neuronal progenitor cells. These progenitor cells serve as a bridge between the patient's own cells and the functional dopamine neurons needed for therapy, allowing for autologous transplantation that avoids immune rejection while providing the missing neuronal population.
2Productivity
If conventional differentiation methods are used to generate midbrain dopamine cells from iPSCs, then cell production is achieved, but significant cell loss occurs
Solution Approach 1:
The patent applies preliminary action by pre-differentiating iPSCs into midbrain dopamine neuronal progenitor cells with specific molecular characteristics before transplantation. The cells are prepared in advance with appropriate lineage commitment and maturation markers, ensuring they are ready for functional integration upon implantation while minimizing the time and cell loss associated with post-transplantation differentiation.
Solution Approach 2:
The patent employs parameter changes by systematically optimizing differentiation conditions including growth factor concentrations, culture medium composition, and signaling pathway modulators. These parameter adjustments guide iPSCs through controlled differentiation stages, maximizing the yield of functional midbrain dopamine progenitor cells while minimizing cell death and maintaining high viability throughout the differentiation process.
3Quantity of substance
If undifferentiated cells remain in the transplanted population, then cell quantity is maintained, but neoplastic potential increases
Solution Approach 1:
The patent extracts undifferentiated cells from the transplanted population through rigorous quality control measures including immunophenotypic characterization and functional assays. By removing cells that have not fully differentiated into the midbrain dopamine neuronal lineage, the protocol eliminates the neoplastic risk while preserving the therapeutic cell population, ensuring safety without compromising the quantity of functional cells available for transplantation.
4Stability of the object's composition
If high-density cell plating is used to maintain cell isolation, then cellular organization is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by plating cells at high density in discrete, spatially separated areas rather than as a continuous monolayer. This segmentation maintains cellular isolation and promotes proper neuronal organization and network formation while being implementable using standard tissue culture techniques. The approach divides the culture space into distinct zones that facilitate controlled cell-cell interactions and simplify manufacturing processes.
Data Source
AI summary
Methods for generating midbrain dopamine (mDA) neuronal progenitor cells useful for autologous cell therapy in Parkinson's Disease, compositions comprising the cells, and methods of use thereof.